• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Clene downgraded by Oppenheimer

    10/4/22 8:58:30 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email
    Oppenheimer downgraded Clene from Outperform to Perform
    Get the next $CLNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLNN

    DatePrice TargetRatingAnalyst
    10/4/2022Outperform → Perform
    Oppenheimer
    7/18/2022$16.00Buy
    H.C. Wainwright
    5/2/2022$10.00Buy
    Canaccord Genuity
    9/28/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner General Resonance Llc sold $2,424 worth of shares (600 units at $4.04), decreasing direct ownership by 0.08% to 707,992 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      6/4/25 3:23:07 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner General Resonance Llc sold $2,473 worth of shares (600 units at $4.12), decreasing direct ownership by 0.08% to 708,592 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      6/2/25 2:39:49 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner General Resonance Llc sold $1,148 worth of shares (410 units at $2.80), decreasing direct ownership by 0.06% to 709,192 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      5/30/25 2:40:28 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Clene downgraded by Oppenheimer

      Oppenheimer downgraded Clene from Outperform to Perform

      10/4/22 8:58:30 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Clene with a new price target

      H.C. Wainwright initiated coverage of Clene with a rating of Buy and set a new price target of $16.00

      7/18/22 7:19:07 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Clene with a new price target

      Canaccord Genuity initiated coverage of Clene with a rating of Buy and set a new price target of $10.00

      5/2/22 9:11:11 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Matlin David J bought $438,458 worth of shares (92,307 units at $4.75), increasing direct ownership by 26% to 444,491 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      10/2/24 12:58:21 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Science Officer Mortenson Mark bought $97,432 worth of shares (20,512 units at $4.75), increasing direct ownership by 243% to 28,949 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      10/1/24 4:17:45 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Etherington Robert Dee bought $47,500 worth of shares (10,000 units at $4.75), increasing direct ownership by 33% to 40,149 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      10/1/24 4:17:06 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care